Upon selling his previous biotechnology startup Ken Mulvany’s assets included a number of drugs across various stages of development.
“We had a pipeline of a couple of phase two assets, a couple of phase one assets, and maybe four or five pre-clinical assets. It took me a lot of time and money to get them to this stage. A decade.”
Fast forward to his current business, BenevolentAI, and within just 18 months his pipeline has the same number of assets as his previous business took to achieve in a decade. Thanks to AI.
Convinced of the impact of AI on healthcare yet?
